Emergent BioSolutions
EBS
$2.18
Share price
-4.80%
Change (1 day)
-78.50%
Change (1 year)
Categories
P/S ratio for Emergent BioSolutions (EBS)
P/S ratio as of April 2024 (TTM): 0.1116
According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.111557. At the end of 2023 the company had a P/S ratio of 0.1216.
P/S ratio history for Emergent BioSolutions from 2006 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.1216 | -77.72% |
| 2022 | 0.5458 | -61.29% |
| 2021 | 1.41 | -57.23% |
| 2020 | 3.30 | 16.26% |
| 2019 | 2.84 | -34.1% |
| 2018 | 4.30 | -8.98% |
| 2017 | 4.73 | 22.78% |
| 2016 | 3.85 | -3.92% |
| 2015 | 4.01 | 32.41% |
| 2014 | 3.03 | -7.29% |
| 2013 | 3.26 | -3.47% |
| 2012 | 3.38 | 52.71% |
| 2011 | 2.21 | -22.84% |
| 2010 | 2.87 | 60.83% |
| 2009 | 1.78 | -59.21% |
| 2008 | 4.38 | 431.65% |
| 2007 | 0.8230 | -53.78% |
| 2006 | 1.78 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.54 | 2,179.51% | 🇺🇸 USA |
 Merck MRK | 5.35 | 4,697.02% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.21 | 1,877.07% | 🇬🇧 UK |
 Soligenix SNGX | 6.50 | 5,725.31% | 🇺🇸 USA |
 SIGA Technologies SIGA | 4.40 | 3,844.29% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 353 | 316,651.08% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9299 | 733.59% | 🇮🇱 Israel |